Weight Loss on GLP-1 Drugs Linked to Lower Risk of Disease, Study Finds

A University of Liverpool analysis of nearly 90,000 U.S. patients found that greater BMI loss on GLP-1 or GLP-1/GIP drugs was linked to better health outcomes.

Patients who lost more weight over one year had lower rates of sleep apnea, chronic kidney disease, osteoarthritis, and heart failure.

Those who gained weight on the medications tended to have worse outcomes, underscoring that the benefit depends on actual weight loss.

The findings, presented at the European Congress on Obesity, suggest drugs like Ozempic, Wegovy, and Mounjaro may reduce obesity-related disease risk most when weight loss is substantial and sustained.